20854 Federal Register / Vol. 75, No. 76 / Wednesday, April 21, 2010 / Notices 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Eye Institute 

Special Emphasis Panel, Immunosuppression 

for Eye Diseases. 

Date: April 20, 2010. 

Time: 3 p.m. to 4 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Eye Institute, 5635 Fishers 

Lane, 1300, Bethesda, MD 20892. 

Contact Person: Samuel Rawlings, PhD, 

Chief, Scientific Review Branch, Division of 

Extramural Research, National Eye Institute, 

5635 Fishers Lane, Suite 1300, MSC 9300, 

Bethesda, MD 20892–9300, 301–451–2020, 

rawlings@nei.nih.gov. 

This notice is being published less than 15 

days prior to the meeting due to the timing 

limitations imposed by the review and 

funding cycle. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93867, Vision Research, 

National Institutes of Health, HHS) 

Dated: April 8, 2010. 

Jennifer Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2010–8846 Filed 4–20–10; 8:45 am] 

BILLING CODE 4140–01–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Agency for Healthcare Research and 

Quality 

Notice of Meeting 

In accordance with section 10(d) of 

the Federal Advisory Committee Act (5 

U.S.C., Appendix 2), announcement is 

made of a Health Care Policy and 

Research Special Emphasis Panel (SEP) 

meeting. 

A Special Emphasis Panel is a group 

of experts in fields related to health care 

research who are invited by the Agency 

for Healthcare Research and Quality 

(AHRQ), and agree to be available, to 

conduct on an as needed basis, 

scientific reviews of applications for 

AHRQ support. Individual members of 

the Panel do not attend regularlyscheduled meetings and do not serve for 

fixed terms or a long period of time. 

Rather, they are asked to participate in 

particular review meetings which 

require their type of expertise. 

Substantial segments of the upcoming 

SEP meeting listed below will be closed 

to the public in accordance with the 

Federal Advisory Committee Act, 

section 10(d) of 5 U.S.C., Appendix 2 

and 5 U.S.C. 552b(c)(6). Grant 

applications for the Recovery Act 2009 

Limited Competition: AHRQ Clinical 

and Health Outcomes Initiative in 

Comparative Effectiveness (CHOICE) 

Grants (R01) applications are to be 

reviewed and discussed at this meeting. 

These discussions are likely to reveal 

personal information concerning 

individuals associated with the 

applications. This information is 

exempt from mandatory disclosure 

under the above-cited statutes. 

SEP Meeting on: Recovery Act 2009 

Limited Competition: AHRQ Clinical and 

Health Outcomes Initiative in Comparative 

Effectiveness (CHOICE) Grants (R01). 

Date: April 28–30, 2010 (Open on April 28 

from 8 a.m. to 8:15 a.m. and closed for the 

remainder of the meeting). 

Place: Doubletree Bethesda Hotel & 

Executive Meeting Center, 8120 Wisconsin 

Avenue, Conference Room TBD, Bethesda, 

Maryland 20852. 

Contact Person: Anyone wishing to obtain 

a roster of members, agenda or minutes of the 

nonconfidential portions of this meeting 

should contact Mrs. Bonnie Campbell, 

Committee Management Officer, Office of 

Extramural Research, Education and Priority 

Populations, AHRQ, 540 Gaither Road, Room 

2038, Rockville, Maryland 20850, Telephone 

(301) 427–1554. 

Agenda items for this meeting are subject 

to change as priorities dictate. 

This notice is published less than 15 days 

in advance of the meeting date due to 

logistical difficulties. 

Dated: April 13, 2010. 

Carol M. Clancy, 

Director. 

[FR Doc. 2010–9035 Filed 4–20–10; 8:45 am] 

BILLING CODE 4160–90–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Food and Drug Administration 

[Docket No. FDA–2010–N–0202] 

Medical Device Use in the Home 

Environment: Implications for the Safe 

and Effective Use of Medical Device 

Technology Migrating Into the Home; 

Public Workshop; Request for 

Comments 

AGENCY: Food and Drug Administration, 

HHS. 

ACTION: Notice of public workshop; 

request for comments. 

The Food and Drug Administration 

(FDA) is announcing a public workshop 

entitled Medical Device Use in the 

Home Environment: Implications for the 

Safe and Effective Use of Medical 

Device Technology Migrating Into the 

Home. The purpose of the workshop is 

to solicit information from healthcare 

providers, academics, human factors 

experts, medical device manufacturers 

and distributors, professional societies, 

patient advocacy groups, patients, and 

caregivers, on the challenges 

surrounding medical device technology 

in the home environment. FDA seeks 

input and comments on a number of 

identified topics related to medical 

device home use. 

Dates and Times: The public 

workshop will be held on May 24, 2010, 

from 7:30 a.m. to 5 p.m. Persons 

interested in attending and/or 

participating in the workshop must 

register by 5 p.m. on May 17, 2010. 

Submit written or electronic comments 

by June 30, 2010. 

Location: The public workshop will 

be held at the Hilton Hotel, 8727 

Colesville Rd., Silver Spring, MD 20910. 

The hotel’s front desk telephone number 

is 301–589–5200. 

Contact Person: Mary Brady, Center 

for Devices and Radiological Health, 

Food and Drug Administration, 10903 

New Hampshire Ave., Bldg. 66, rm. 

2320, Silver Spring, MD 20993–0002, email: Mary.Brady@fda.hhs.gov 

(preferable), 301–796–6089. 

Registration and Requests for Oral 

Comments: If you wish to attend the 

public meeting, you must register online 

at http://www.fda.gov/MedicalDevices/ 

NewsEvents/WorkshopsConferences/ 

default.htm (select the appropriate 

meeting from the list). Please provide 

complete contact information for each 

attendee, including name, title, 

organization or company, address, email, and telephone number. 

Registrations must be submitted by May 

17, 2010. 

If you wish to make an oral comment 

during general sessions of the public 

workshop (see section III of this 

document), you must indicate this in 

your registration. Please also identify 

which topics you wish to address in 

your oral comment. Topics for 

discussion are listed in section II of this 

document. FDA will do its best to 

accommodate all persons who wish to 

make oral comments during the general 

sessions. However, FDA strongly 

recommends that you provide written or 

electronic comments as instructed in 

this document to ensure that your 

comments are captured. Please refer to 

the section entitled Comments for 

instructions on submitting written or 

electronic comments. 

Registration is free and will be on a 

first-come, first-served basis. Early 

registration is encouraged because 

seating is limited. There will be no 

onsite registration. 


erowe on DSK5CLS3C1PROD with NOTICES